Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 long-term study of AZD0585 in Japanese patients with hyperlipidemia and hypertriglyceridemia
jRCT2080222886Phase 3
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omega-3-carboxylic acids in hyperlipidemia and hypertriglyceridemia (3 arms), sponsored by AstraZeneca.
02
Drugs
omega-3-carboxylic acids
03
Conditions
hyperlipidemiahypertriglyceridemia
Beyond the preview
Go deeper on jRCT2080222886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222886.